Chaperoning steroidal physiology: Lessons from mouse genetic models of Hsp90 and its cochaperones

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1823, Issue 3, 2012, Pages 722-729

  Sanchez, Edwin R ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

FKBP51; FKBP52; Hsp90; P23; Protein phosphatase 5; Steroids

Indexed keywords

ANDROGEN RECEPTOR; CHAPERONE; CYCLOPHILIN; CYCLOPHILIN 40 PROTEIN; ESTROGEN RECEPTOR; FK 506 BINDING PROTEIN; FK 506 BINDING PROTEIN 51; FK 506 BINDING PROTEIN 52; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90ALPHA; HEAT SHOCK PROTEIN 90BETA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHOPROTEIN PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE 5; PROGESTERONE RECEPTOR; PROSTAGLANDIN E2; PROTEIN P23; UNCLASSIFIED DRUG;

ADIPOGENESIS; BINDING SITE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CELL CYCLE ARREST; CHRONIC STRESS; DIET; DNA DAMAGE; ENDOCRINOLOGY; FERTILITY; GENETIC MODEL; GENETIC TRANSCRIPTION; GLUCONEOGENESIS; HUMAN; MOLECULAR GENETICS; NONHUMAN; NUCLEOTIDE SEQUENCE; OBESITY; ORGANOGENESIS; PHENOTYPE; POSTTRAUMATIC STRESS DISORDER; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; TETRATRICOPEPTIDE REPEAT;

ANIMALS; HSP90 HEAT-SHOCK PROTEINS; MICE; MODELS, GENETIC; MOLECULAR CHAPERONES; RECEPTORS, STEROID;

EUKARYOTA; MUS;

EID: 84857042430     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2011.11.006     Document Type: Review

References (100)

1. Sanchez E.R., Toft D.O., Schlesinger M.J., Pratt W.B. Evidence that the 90-kDa phosphoprotein associated with the untransformed L-cell glucocorticoid receptor is a murine heat shock protein. J. Biol. Chem. 1985, 260:12398-12401.
2. Catelli M.G., Binart N., Jung-Testas I., Renoir J.M., Baulieu E.E., Feramisco J.R., Welch W.J. The common 90-kd protein component of non-transformed '8S' steroid receptors is a heat-shock protein. EMBO J. 1985, 4:3131-3135.
3. Schuh S., Yonemoto W., Brugge J., Bauer V.J., Riehl R.M., Sullivan W.P., Toft D.O. A 90,000-dalton binding protein common to both steroid receptors and the Rous sarcoma virus transforming protein, pp 60v-src. J. Biol. Chem. 1985, 260:14292-14296.
4. Pratt W.B., Toft D.O. Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr. Rev. 1997, 18(3):306-360.
5. Picard D. Chaperoning steroid hormone action. Trends Endocrinol. Metab. 2006, 17:229-235.
6. Dalman F.C., Koenig R.J., Perdew G.H., Massa E., Pratt W.B. In contrast to the glucocorticoid receptor, the thyroid hormone receptor is translated in the DNA binding state and is not associated with hsp90. J. Biol. Chem. 1990, 265:3615-3618.
7. Sumanasekera W.K., Tien E.S., Turpey R., Vanden Heuvel J.P., Perdew G.H. Evidence that peroxisome proliferator-activated receptor alpha is complexed with the 90-kDa heat shock protein and the hepatitis virus B X-associated protein 2. J. Biol. Chem. 2003, 278:4467-4473.
8. Sumanasekera W.K., Tien E.S., Davis J.W.n., Turpey R., Perdew G.H., Vanden Heuvel J.P. Heat shock protein-90 (Hsp90) acts as a repressor of peroxisome proliferator-activated receptor-alpha (PPARalpha) and PPARbeta activity. Biochemistry 2003, 42:10726-10735.
9. Chen H.S., Singh S.S., Perdew G.H. The Ah receptor is a sensitive target of geldanamycin-induced protein turnover. Arch. Biochem. Biophys. 1997, 348:190-198.
10. Yoshinari K., Kobayashi K., Moore R., Kawamoto T., Negishi M. Identification of the nuclear receptor CAR:HSP90 complex in mouse liver and recruitment of protein phosphatase 2A in response to phenobarbital. FEBS Lett. 2003, 548:17-20.
11. Squires E.J., Sueyoshi T., Negishi M. Cytoplasmic localization of pregnane X receptor and ligand-dependent nuclear translocation in mouse liver. J. Biol. Chem. 2004, 279:49307-49314.
12. Angelo G., Lamon-Fava S., Sonna L.A., Lindauer M.L., Wood R.J. Heat shock protein 90beta: a novel mediator of vitamin D action. Biochem. Biophys. Res. Commun. 2008, 367:578-583.
13. Buchner J., Hsp90 & Co. A holding for folding. Trends Biochem. Sci. 1999, 24:136-141.
14. Grenert J.P., Sullivan W.P., Fadden P., Haystead T.A., Clark J., Mimnaugh E., Krutzsch H., Ochel H.J., Schulte T.W., Sausville E., Neckers L.M., Toft D.O. The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. J. Biol. Chem. 1997, 272:23843-23850.
15. Bresnick E.H., Dalman F.C., Sanchez E.R., Pratt W.B. Evidence that the 90-kDa heat shock protein is necessary for the steroid binding conformation of the L cell glucocorticoid receptor. J. Biol. Chem. 1989, 264:4992-4997.
16. Scherrer L.C., Dalman F.C., Massa E., Meshinchi S., Pratt W.B. Structural and functional reconstitution of the glucocorticoid receptor-hsp90 complex. J. Biol. Chem. 1990, 265:21397-21400.
17. Tai P.K., Maeda Y., Nakao K., Wakim N.G., Duhring J.L., Faber L.E. A 59-kilodalton protein associated with progestin, estrogen, androgen, and glucocorticoid receptors. Biochemistry 1986, 25:5269-5275.
18. Smith D.F., Baggenstoss B.A., Marion T.N., Rimerman R.A. Two FKBP-related proteins are associated with progesterone receptor complexes. J. Biol. Chem. 1993, 268:18365-18371.
19. Ratajczak T., Carrello A., Mark P.J., Warner B.J., Simpson R.J., Moritz R.L., House A.K. The cyclophilin component of the unactivated estrogen receptor contains a tetratricopeptide repeat domain and shares identity with p59 (FKBP59). J. Biol. Chem. 1993, 268:13187-13192.
20. Chen M.S., Silverstein A.M., Pratt W.B., Chinkers M. The tetratricopeptide repeat domain of protein phosphatase 5 mediates binding to glucocorticoid receptor heterocomplexes and acts as a dominant negative mutant. J. Biol. Chem. 1996, 271:32315-32320.
21. McKeen H.D., McAlpine K., Valentine A., Quinn D.J., McClelland K., Byrne C., O'Rourke M., Young S., Scott C.J., McCarthy H.O., Hirst D.G., Robson T. A novel FK506-like binding protein interacts with the glucocorticoid receptor and regulates steroid receptor signaling. Endocrinology 2008, 149:5724-5734.
22. Picard D., Khursheed B., Garabedian M.J., Fortin M.G., Lindquist S., Yamamoto K.R. Reduced levels of hsp90 compromise steroid receptor action in vivo. Nature 1990, 348:166-168.
23. Sreedhar A.S., Kalmar E., Csermely P., Shen Y.F. Hsp90 isoforms: functions, expression and clinical importance. FEBS Lett. 2004, 562:11-15.
24. Grad I., Cederroth C.R., Walicki J., Grey C., Barluenga S., Winssinger N., De Massy B., Nef S., Picard D. The molecular chaperone Hsp90alpha is required for meiotic progression of spermatocytes beyond pachytene in the mouse. PLoS One 2010, 5:e15770.
25. Taherian A., Krone P.H., Ovsenek N. A comparison of Hsp90alpha and Hsp90beta interactions with cochaperones and substrates. Biochem. Cell Biol. 2008, 86:37-45.
26. Bouchier-Hayes L., Oberst A., McStay G.P., Connell S., Tait S.W., Dillon C.P., Flanagan J.M., Beere H.M., Green D.R. Characterization of cytoplasmic caspase-2 activation by induced proximity. Mol. Cell 2009, 35:830-840.
27. Eustace B.K., Sakurai T., Stewart J.K., Yimlamai D., Unger C., Zehetmeier C., Lain B., Torella C., Henning S.W., Beste G., Scroggins B.T., Neckers L., Ilag L.L., Jay D.G. Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nat. Cell Biol. 2004, 6:507-514.
28. Voss A.K., Thomas T., Gruss P. Mice lacking HSP90beta fail to develop a placental labyrinth. Development 2000, 127:1-11.
29. Smith D.F., Faber L.E., Toft D.O. Purification of unactivated progesterone receptor and identification of novel receptor-associated proteins. J. Biol. Chem. 1990, 265:3996-4003.
30. Bresnick E.H., Dalman F.C., Pratt W.B. Direct stoichiometric evidence that the untransformed Mr 300,000, 9S, glucocorticoid receptor is a core unit derived from a larger heteromeric complex. Biochemistry 1990, 29:520-527.
31. Pratt W.B., Galigniana M.D., Morishima Y., Murphy P.J. Role of molecular chaperones in steroid receptor action. Essays Biochem. 2004, 40:41-58.
32. Smith D.F., Toft D.O. Minireview: the intersection of steroid receptors with molecular chaperones: observations and questions. Mol. Endocrinol. 2008, 22(10):2229-2240.
33. Freeman B.C., Felts S.J., Toft D.O., Yamamoto K.R. The p23 molecular chaperones act at a late step in intracellular receptor action to differentially affect ligand efficacies. Genes Dev. 2000, 14:422-434.
34. Wochnik G.M., Young J.C., Schmidt U., Holsboer F., Hartl F.U., Rein T. Inhibition of GR-mediated transcription by p23 requires interaction with Hsp90. FEBS Lett. 2004, 560:35-38.
35. Oxelmark E., Roth J.M., Brooks P.C., Braunstein S.E., Schneider R.J., Garabedian M.J. The cochaperone p23 differentially regulates estrogen receptor target genes and promotes tumor cell adhesion and invasion. Mol. Cell. Biol. 2006, 26:5205-5213.
36. Tanioka T., Nakatani Y., Semmyo N., Murakami M., Kudo I. Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis. J. Biol. Chem. 2000, 275:32775-32782.
37. Toogun O.A., Zeiger W., Freeman B.C. The p23 molecular chaperone promotes functional telomerase complexes through DNA dissociation. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:5765-5770.
38. Grad I., McKee T.A., Ludwig S.M., Hoyle G.W., Ruiz P., Wurst W., Floss T., Miller C.A.r., Picard D. The Hsp90 cochaperone p23 is essential for perinatal survival. Mol. Cell. Biol. 2006, 26:8976-8983.
39. Cole T.J., Blendy J.A., Monaghan A.P., Krieglstein K., Schmid W., Aguzzi A., Fantuzzi G., Hummler E., Unsicker K., Schutz G. Targeted disruption of the glucocorticoid receptor gene blocks adrenergic chromaffin cell development and severely retards lung maturation. Genes Dev. 1995, 9:1608-1621.
40. Bayo P., Sanchis A., Bravo A., Cascallana J.L., Buder K., Tuckermann J., Schutz G., Perez P. Glucocorticoid receptor is required for skin barrier competence. Endocrinology 2008, 149:1377-1388.
41. Nakatani Y., Hokonohara Y., Kakuta S., Sudo K., Iwakura Y., Kudo I. Knockout mice lacking cPGES/p23, a constitutively expressed PGE2 synthetic enzyme, are peri-natally lethal. Biochem. Biophys. Res. Commun. 2007, 362:387-392.
42. Lovgren A.K., Kovarova M., Koller B.H. cPGES/p23 is required for glucocorticoid receptor function and embryonic growth but not prostaglandin E2 synthesis. Mol. Cell. Biol. 2007, 27:4416-4430.
43. Nakatani Y., Hokonohara Y., Tajima Y., Kudo I., Hara S. Involvement of the constitutive prostaglandin E synthase cPGES/p23 in expression of an initial prostaglandin E2 inactivating enzyme, 15-PGDH. Prostaglandins Other Lipid Mediat. 2011, 94:112-117.
44. Sugimoto Y., Narumiya S. Prostaglandin E receptors. J. Biol. Chem. 2007, 282:11613-11617.
45. Bolt R.J., van Weissenbruch M.M., Lafeber H.N., Delemarre-van de Waal H.A. Glucocorticoids and lung development in the fetus and preterm infant. Pediatr. Pulmonol. 2001, 32:76-91.
46. Lee J., Kim H.J., Moon J.A., Sung Y.H., Baek I.J., Roh J.I., Ha N.Y., Kim S.Y., Bahk Y.Y., Lee J.E., Yoo T.H., Lee H.W. Transgenic overexpression of p23 induces spontaneous hydronephrosis in mice. Int. J. Exp. Pathol. 2011, 92:251-259.
47. Davies T.H., Sanchez E.R. Fkbp52. Int. J. Biochem. Cell Biol. 2005, 37(1):42-47.
48. Nakao K., Myers J.E., Faber L.E. Development of a monoclonal antibody to the rabbit 8.5S uterine progestin receptor. Can. J. Biochem. Cell Biol. 1985, 63:33-40.
49. Renoir J.M., Radanyi C., Faber L.E., Baulieu E.E. The non-DNA-binding heterooligomeric form of mammalian steroid hormone receptors contains a hsp90-bound 59-kilodalton protein. J. Biol. Chem. 1990, 265:10740-10745.
50. Sanchez E.R., Faber L.E., Henzel W.J., Pratt W.B. The 56-59-kilodalton protein identified in untransformed steroid receptor complexes is a unique protein that exists in cytosol in a complex with both the 70- and 90-kilodalton heat shock proteins. Biochemistry 1990, 29:5145-5152.
51. Riggs D.L., Roberts P.J., Chirillo S.C., Cheung-Flynn J., Prapapanich V., Ratajczak T., Gaber R., Picard D., Smith D.F. The Hsp90-binding peptidylprolyl isomerase FKBP52 potentiates glucocorticoid signaling in vivo. EMBO J. 2003, 22:1158-1167.
52. Wochnik G.M., Ruegg J., Abel G.A., Schmidt U., Holsboer F., Rein T. FK506-binding proteins 51 and 52 differentially regulate dynein interaction and nuclear translocation of the glucocorticoid receptor in mammalian cells. J. Biol. Chem. 2005, 280:4609-4616.
53. Davies T.H., Ning Y.M., Sanchez E.R. Differential control of glucocorticoid receptor hormone-binding function by tetratricopeptide repeat (TPR) proteins and the immunosuppressive ligand FK506. Biochemistry 2005, 44:2030-2038.
54. Yang Z., Wolf I.M., Chen H., Periyasamy S., Chen Z., Yong W., Shi S., Zhao W., Xu J., Srivastava A., Sanchez E.R., Shou W. FK506-binding protein 52 is essential to uterine reproductive physiology controlled by the progesterone receptor a isoform. Mol. Endocrinol. 2006, 20:2682-2694.
55. Wolf I.M., Periyasamy S., Hinds T.D., Yong W., Shou W., Sanchez E.R. Targeted ablation reveals a novel role of FKBP52 in gene-specific regulation of glucocorticoid receptor transcriptional activity. J. Steroid Biochem. Mol. Biol. 2009, 113:36-45.
56. Riggs D.L., Cox M.B., Tardif H.L., Hessling M., Buchner J., Smith D.F. Noncatalytic role of the FKBP52 peptidyl-prolyl isomerase domain in the regulation of steroid hormone signaling. Mol. Cell. Biol. 2007, 27:8658-8669.
57. Cheung-Flynn J., Prapapanich V., Cox M.B., Riggs D.L., Suarez-Quian C., Smith D.F. Physiological role for the cochaperone FKBP52 in androgen receptor signaling. Mol. Endocrinol. 2005, 19:1654-1666.
58. Galigniana M.D., Erlejman A.G., Monte M., Gomez-Sanchez C., Piwien-Pilipuk G. The hsp90-FKBP52 complex links the mineralocorticoid receptor to motor proteins and persists bound to the receptor in early nuclear events. Mol. Cell. Biol. 2010, 30:1285-1298.
59. Banerjee A., Periyasamy S., Wolf I.M., Hinds T.D.J., Yong W., Shou W., Sanchez E.R. Control of glucocorticoid and progesterone receptor subcellular localization by the ligand-binding domain is mediated by distinct interactions with tetratricopeptide repeat proteins. Biochemistry 2008, 47:10471-10480.
60. Warrier M., Hinds T.D.J., Ledford K.J., Cash H.A., Patel P.R., Bowman T.A., Stechschulte L.A., Yong W., Shou W., Najjar S.M., Sanchez E.R. Susceptibility to diet-induced hepatic steatosis and glucocorticoid resistance in FK506-binding protein 52-deficient mice. Endocrinology 2010, 151:3225-3236.
61. Yong W., Yang Z., Periyasamy S., Chen H., Yucel S., Li W., Lin L.Y., Wolf I.M., Cohn M.J., Baskin L.S., Sanchez E.R., Shou W. Essential role for Co-chaperone Fkbp52 but not Fkbp51 in androgen receptor-mediated signaling and physiology. J. Biol. Chem. 2007, 282:5026-5036.
62. Chen H., Yong W., Hinds T.D.J., Yang Z., Zhou Y., Sanchez E.R., Shou W. Fkbp52 regulates androgen receptor transactivation activity and male urethra morphogenesis. J. Biol. Chem. 2010, 285:27776-27784.
63. Tranguch S., Cheung-Flynn J., Daikoku T., Prapapanich V., Cox M.B., Xie H., Wang H., Das S.K., Smith D.F., Dey S.K. Cochaperone immunophilin FKBP52 is critical to uterine receptivity for embryo implantation. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:14326-14331.
64. Tranguch S., Wang H., Daikoku T., Xie H., Smith D.F., Dey S.K. FKBP52 deficiency-conferred uterine progesterone resistance is genetic background and pregnancy stage specific. J. Clin. Invest. 2007, 117:1824-1834.
65. Hirota Y., Tranguch S., Daikoku T., Hasegawa A., Osuga Y., Taketani Y., Dey S.K. Deficiency of immunophilin FKBP52 promotes endometriosis. Am. J. Pathol. 2008, 173:1747-1757.
66. Hirota Y., Acar N., Tranguch S., Burnum K.E., Xie H., Kodama A., Osuga Y., Ustunel I., Friedman D.B., Caprioli R.M., Daikoku T., Dey S.K. Uterine FK506-binding protein 52 (FKBP52)-peroxiredoxin-6 (PRDX6) signaling protects pregnancy from overt oxidative stress. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:15577-15582.
67. Stechschulte L.A., Sanchez E.R. FKBP51-a selective modulator of glucocorticoid and androgen sensitivity. Curr. Opin. Pharmacol. 2011, 11:332-337.
68. Hubler T.R., Denny W.B., Valentine D.L., Cheung-Flynn J., Smith D.F., Scammell J.G. The FK506-binding immunophilin FKBP51 is transcriptionally regulated by progestin and attenuates progestin responsiveness. Endocrinology 2003, 144:2380-2387.
69. Febbo P.G., Lowenberg M., Thorner A.R., Brown M., Loda M., Golub T.R. Androgen mediated regulation and functional implications of fkbp51 expression in prostate cancer. J. Urol. 2005, 173:1772-1777.
70. Ni L., Yang C.S., Gioeli D., Frierson H., Toft D.O., Paschal B.M. FKBP51 promotes assembly of the Hsp90 chaperone complex and regulates androgen receptor signaling in prostate cancer cells. Mol. Cell. Biol. 2010, 30:1243-1253.
71. Periyasamy S., Hinds T.J., Shemshedini L., Shou W., Sanchez E.R. FKBP51 and Cyp40 are positive regulators of androgen-dependent prostate cancer cell growth and the targets of FK506 and cyclosporin A. Oncogene 2010, 29:1691-1701.
72. Zhu W., Zhang J.S., Young C.Y. Silymarin inhibits function of the androgen receptor by reducing nuclear localization of the receptor in the human prostate cancer cell line LNCaP. Carcinogenesis 2001, 22:1399-1403.
73. Vanaja D.K., Mitchell S.H., Toft D.O., Young C.Y. Effect of geldanamycin on androgen receptor function and stability. Cell Stress Chaperones 2002, 7:55-64.
74. Clegg N., Eroglu B., Ferguson C., Arnold H., Moorman A., Nelson P.S. Digital expression profiles of the prostate androgen-response program. J. Steroid Biochem. Mol. Biol. 2002, 80:13-23.
75. Velasco A.M., Gillis K.A., Li Y., Brown E.L., Sadler T.M., Achilleos M., Greenberger L.M., Frost P., Bai W., Zhang Y. Identification and validation of novel androgen-regulated genes in prostate cancer. Endocrinology 2004, 145:3913-3924.
76. Magee J.A., Chang L.W., Stormo G.D., Milbrandt J. Direct, androgen receptor-mediated regulation of the FKBP5 gene via a distal enhancer element. Endocrinology 2006, 147:590-598.
77. Makkonen H., Kauhanen M., Paakinaho V., Jaaskelainen T., Palvimo J.J. Long-range activation of FKBP51 transcription by the androgen receptor via distal intronic enhancers. Nucleic Acids Res. 2009, 37:4135-4148.
78. Amler L.C., Agus D.B., LeDuc C., Sapinoso M.L., Fox W.D., Kern S., Lee D., Wang V., Leysens M., Higgins B., Martin J., Gerald W., Dracopoli N., Cordon-Cardo C., Scher H.I., Hampton G.M. Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1. Cancer Res. 2000, 60:6134-6141.
79. Drago A., De Ronchi D., Serretti A. Pharmacogenetics of antidepressant response: an update. Hum. Genomics 2009, 3:257-274.
80. Binder E.B., Salyakina D., Lichtner P., Wochnik G.M., Ising M., Putz B., Papiol S., Seaman S., Lucae S., Kohli M.A., Nickel T., Kunzel H.E., Fuchs B., Majer M., Pfennig A., Kern N., Brunner J., Modell S., Baghai T., Deiml T., Zill P., Bondy B., Rupprecht R., Messer T., Kohnlein O., Dabitz H., Bruckl T., Muller N., Pfister H., Lieb R., Mueller J.C., Lohmussaar E., Strom T.M., Bettecken T., Meitinger T., Uhr M., Rein T., Holsboer F., Muller-Myhsok B. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat. Genet. 2004, 36:1319-1325.
81. Ising M., Depping A.M., Siebertz A., Lucae S., Unschuld P.G., Kloiber S., Horstmann S., Uhr M., Muller-Myhsok B., Holsboer F. Polymorphisms in the FKBP5 gene region modulate recovery from psychosocial stress in healthy controls. Eur. J. Neurosci. 2008, 28:389-398.
82. Kirchheiner J., Lorch R., Lebedeva E., Seeringer A., Roots I., Sasse J., Brockmoller J. Genetic variants in FKBP5 affecting response to antidepressant drug treatment. Pharmacogenomics 2008, 9:841-846.
83. Binder E.B., Bradley R.G., Liu W., Epstein M.P., Deveau T.C., Mercer K.B., Tang Y., Gillespie C.F., Heim C.M., Nemeroff C.B., Schwartz A.C., Cubells J.F., Ressler K.J. Association of FKBP5 polymorphisms and childhood abuse with risk of posttraumatic stress disorder symptoms in adults. JAMA 2008, 299:1291-1305.
84. Hartmann J., Wagner K.V., Liebl C., Scharf S.H., Wang X.D., Wolf M., Hausch F., Rein T., Schmidt U., Touma C., Cheung-Flynn J., Cox M.B., Smith D.F., Holsboer F., Muller M.B., Schmidt M.V. The involvement of FK506-binding protein 51 (FKBP5) in the behavioral and neuroendocrine effects of chronic social defeat stress. Neuropharmacology 2012, 62:332-339.
85. Pei H., Li L., Fridley B.L., Jenkins G.D., Kalari K.R., Lingle W., Petersen G., Lou Z., Wang L. FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell 2009, 16:259-266.
86. Pessin J.E., Saltiel A.R. Signaling pathways in insulin action: molecular targets of insulin resistance. J. Clin. Invest. 2000, 106:165-169.
87. Hinds T.D., Sanchez E.R. Protein phosphatase 5. Int. J. Biochem. Cell Biol. 2008, 40(11):2358-2362.
88. Golden T., Swingle M., Honkanen R.E. The role of serine/threonine protein phosphatase type 5 (PP5) in the regulation of stress-induced signaling networks and cancer. Cancer Metastasis Rev. 2008, 27:169-178.
89. Yong W., Bao S., Chen H., Li D., Sanchez E.R., Shou W. Mice lacking protein phosphatase 5 are defective in ataxia telangiectasia mutated (ATM)-mediated cell cycle arrest. J. Biol. Chem. 2007, 282:14690-14694.
90. Gergs U., Boknik P., Buchwalow I.B., Fabritz L., Grundker N., Kucerova D., Matus M., Werner F., Schmitz W., Neumann J. Modulation of cardiac contractility by serine/threonine protein phosphatase type 5. Int. J. Cardiol. 2010, Sep 27 [Electronic publication ahead of print].
91. Urban G., Golden T., Aragon I.V., Scammell J.G., Dean N.M., Honkanen R.E. Identification of an estrogen-inducible phosphatase (PP5) that converts MCF-7 human breast carcinoma cells into an estrogen-independent phenotype when expressed constitutively. J. Biol. Chem. 2001, 276:27638-27646.
92. Urban G., Golden T., Aragon I.V., Cowsert L., Cooper S.R., Dean N.M., Honkanen R.E. Identification of a functional link for the p53 tumor suppressor protein in dexamethasone-induced growth suppression. J. Biol. Chem. 2003, 278:9747-9753.
93. Zhang Y., Leung D.Y., Nordeen S.K., Goleva E. Estrogen inhibits glucocorticoid action via protein phosphatase 5 (PP5) mediated glucocorticoid receptor dephosphorylation. J. Biol. Chem. 2009.
94. Golden T., Aragon I.V., Zhou G., Cooper S.R., Dean N.M., Honkanen R.E. Constitutive over expression of serine/threonine protein phosphatase 5 (PP5) augments estrogen-dependent tumor growth in mice. Cancer Lett. 2004, 215:95-100.
95. Golden T., Aragon I.V., Rutland B., Tucker J.A., Shevde L.A., Samant R.S., Zhou G., Amable L., Skarra D., Honkanen R.E. Elevated levels of Ser/Thr protein phosphatase 5 (PP5) in human breast cancer. Biochim. Biophys. Acta 2008, 1782:259-270.
96. Chen M.X., Cohen P.T. Activation of protein phosphatase 5 by limited proteolysis or the binding of polyunsaturated fatty acids to the TPR domain. FEBS Lett. 1997, 400:136-140.
97. Skinner J., Sinclair C., Romeo C., Armstrong D., Charbonneau H., Rossie S. Purification of a fatty acid-stimulated protein-serine/threonine phosphatase from bovine brain and its identification as a homolog of protein phosphatase 5. J. Biol. Chem. 1997, 272:22464-22471.
98. Kang H., Sayner S.L., Gross K.L., Russell L.C., Chinkers M. Identification of amino acids in the tetratricopeptide repeat and C-terminal domains of protein phosphatase 5 involved in autoinhibition and lipid activation. Biochemistry 2001, 40:10485-10490.
99. Taves M.D., Gomez-Sanchez C.E., Soma K.K. Extra-adrenal glucocorticoids and mineralocorticoids: evidence for local synthesis, regulation, and function. Am. J. Physiol. Endocrinol. Metab. 2011, 301:E11-E24.
100. Yeh S., Tsai M.Y., Xu Q., Mu X.M., Lardy H., Huang K.E., Lin H., Yeh S.D., Altuwaijri S., Zhou X., Xing L., Boyce B.F., Hung M.C., Zhang S., Gan L., Chang C. Generation and characterization of androgen receptor knockout (ARKO) mice: an in vivo model for the study of androgen functions in selective tissues. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:13498-13503.